Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of controlled-release carbidopa/levodopa (Accordion Pill) in fluctuating Parkinson's disease after completion of IN 11 004
MOH_2017-06-13_000516Phase 3Recruiting
- Sponsor
- Intec Pharma Ltd.
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of carbidopa + levodopa in Parkinson's disease (PD), sponsored by Intec Pharma Ltd. Primary endpoints: Long-term safety and Long-term tolerability. Started Feb 2016; status: recruiting.
02
Drugs
carbidopa + levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on MOH_2017-06-13_000516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-13_000516.